Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
September 09 2021 - 8:56AM
Business Wire
– Research collaboration covers multiple
antibody research programs –
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced a broad-based
research collaboration with Boehringer Ingelheim International GmbH
to use Twist’s proprietary antibody libraries to discover
therapeutic antibodies against multiple targets provided by
Boehringer Ingelheim.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210909005694/en/
“Boehringer Ingelheim believes Twist’s ability to generate
potent, diverse therapeutic antibodies by mining its comprehensive
libraries, combined with our extensive capabilities and experience
in drug discovery and development, will enable us to deliver
breakthrough opportunities to patients,” said Clive R. Wood, Ph.D.,
Senior Corporate Vice President and Global Head of Discovery
Research at Boehringer Ingelheim. “We look forward to working with
Twist on molecular targets in a broad range of disease areas,”
added Wood.
Under the terms of the agreement, Twist Biopharma, a division of
Twist, will utilize its “Library of Libraries,” a panel of
synthetic antibody phage display libraries derived only from
sequences that exist in the human body, to identify potential
therapeutic antibody candidates. Twist and Boehringer Ingelheim
will work together to validate and optimize any resulting new
antibody candidates, which could be researched against a range of
therapeutic areas. Boehringer Ingelheim retains exclusive worldwide
rights to develop and commercialize any therapeutic antibodies
discovered as part of the collaboration.
Twist will receive an upfront payment for each program entry. In
addition, Twist has the potential to earn up to a total of $710
million in success-based clinical, regulatory and commercial
milestone payments for the multiple target discovery programs.
“This discovery collaboration with Boehringer Ingelheim covering
numerous targets truly illustrates the power of our antibody
libraries. We have the ability to generate precise antibodies to a
diverse range of targets, which together with Boehringer
Ingelheim’s strength in drug development capabilities, could mean
multiple new more personalized treatments in the future for
patients,” said Emily M. Leproust, Ph.D., CEO and co-founder of
Twist.
About Twist Biopharma
By leveraging our unique ability to manufacture DNA at scale, we
can construct proprietary antibody libraries precisely designed to
match sequences that occur in the human body. This library of
libraries gives our partners an integral and unbiased resource for
antibody therapeutic discovery and optimization. This precise and
rational approach to library fabrication combined with
sophisticated bioinformatics and software expertise expedites
antibody discovery by decreasing risk, increasing speed, and
lowering the failure rate for antibody therapeutic development.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation Twist’s ability to discover
novel therapeutic antibodies against multiple targets and to
achieve any of the clinical, regulatory or commercial milestones,
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2021 and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that
improve the lives of humans and animals. As a leading
research-driven biopharmaceutical company, the company creates
value through innovation in areas of high unmet medical need.
Founded in 1885 and family-owned ever since, Boehringer Ingelheim
takes a long-term perspective. Around 52,000 employees serve more
than 130 markets in the three business areas, Human Pharma, Animal
Health, and Biopharmaceutical Contract Manufacturing.
More information about Boehringer Ingelheim can be found at
www.boehringer-ingelheim.com or in our annual report:
www.annualreport.boehringer-ingelheim.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210909005694/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925-202-6211 media@twistbioscience.com
Boehringer Ingelheim Dr. Reinhard Malin Head of
Communications Innovation Unit Boehringer Ingelheim Corporate
Center GmbH Media + PR P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel Senior Associate Director, Media and Corporate
Reputation Boehringer Ingelheim U.S. Media + PR P: +1 203-791-6672
linda.ruckel@boehringer-ingelheim.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024